Accéder au contenu
Merck

Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator.

Cancer cell (2008-05-06)
Sonia Lain, Jonathan J Hollick, Johanna Campbell, Oliver D Staples, Maureen Higgins, Mustapha Aoubala, Anna McCarthy, Virginia Appleyard, Karen E Murray, Lee Baker, Alastair Thompson, Joanne Mathers, Stephen J Holland, Michael J R Stark, Georgia Pass, Julie Woods, David P Lane, Nicholas J Westwood
RÉSUMÉ

We have carried out a cell-based screen aimed at discovering small molecules that activate p53 and have the potential to decrease tumor growth. Here, we describe one of our hit compounds, tenovin-1, along with a more water-soluble analog, tenovin-6. Via a yeast genetic screen, biochemical assays, and target validation studies in mammalian cells, we show that tenovins act through inhibition of the protein-deacetylating activities of SirT1 and SirT2, two important members of the sirtuin family. Tenovins are active on mammalian cells at one-digit micromolar concentrations and decrease tumor growth in vivo as single agents. This underscores the utility of these compounds as biological tools for the study of sirtuin function as well as their potential therapeutic interest.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anticorps monoclonal anti-α-tubuline antibody produced in mouse, clone DM1A, ascites fluid
Sigma-Aldrich
Anticorps monoclonal anti-tubuline, acétylée antibody produced in mouse, clone 6-11B-1, ascites fluid
Sigma-Aldrich
Anti-Histone H4 Antibody, Upstate®, from rabbit